Cite
HARVARD Citation
Adler, A. et al. (2022). NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma. Lancet. 10 (10), pp. e92-e93. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Adler, A. et al. (2022). NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma. Lancet. 10 (10), pp. e92-e93. [Online].